Terminated PHASE2 INTERVENTIONAL 1-arm NCT02719990

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)

Sponsor: Versartis Inc.

Conditions Adult Growth Hormone Deficiency (AGHD)

Interventions somavaratan

Updated 12 times since 2017 Last updated: Mar 20, 2023 Started: Feb 11, 2016 Primary completion: Jan 11, 2018 Completion: Jan 11, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (PGHD) did not meet its primary endpoint of non-inferiority.

Other terminated trials from Versartis Inc.

More terminations from Versartis Inc.

A PHASE2 clinical study on Adult Growth Hormone Deficiency (AGHD), this trial is terminated or withdrawn. The trial is conducted by Versartis Inc. and has accumulated 12 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
May 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2021 — May 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Mar 2018 — May 2018 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Dec 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Versartis Inc.

Data source: Aravive, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.